Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
about
Motif mediated protein-protein interactions as drug targetsThe orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.p53 as a target in myeloproliferative neoplasms.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Developmental Therapeutics in Myeloproliferative Neoplasms.SOHO State-of-the-Art Update and Next Questions: MPN.
P2860
Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Combination treatment in vitro ...... sitive polycythemia vera cells
@ast
Combination treatment in vitro ...... sitive polycythemia vera cells
@en
type
label
Combination treatment in vitro ...... sitive polycythemia vera cells
@ast
Combination treatment in vitro ...... sitive polycythemia vera cells
@en
prefLabel
Combination treatment in vitro ...... sitive polycythemia vera cells
@ast
Combination treatment in vitro ...... sitive polycythemia vera cells
@en
P2093
P2860
P1433
P1476
Combination treatment in vitro ...... sitive polycythemia vera cells
@en
P2093
Goar Mosoyan
John Mascarenhas
Marina Kremyanskaya
Ronald Hoffman
Vesna Najfeld
Xiaoli Wang
P2860
P304
P356
10.1182/BLOOD-2012-02-410712
P407
P577
2012-08-07T00:00:00Z